Is this fund raising under Regulation A or Title III?

Hello Ram, Quadrant Biosciences is offering this as a Reg A. Thanks, The Quadrant Team

Hi, Your max raise goal is $15M and you stated "Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering." So this is a Reg D offering? Please clarify. Thanks.

Hello Helen, The Quadrant Team, along with the fine people at Wefunder, has spent countless hours reviewing these pages to make sure nothing has slipped through. That being said, the above stated quote, "Quadrant Biosciences Inc is not conducting a Regulation Crowdfunding offering" has been removed from the webpage. We are conducting a Reg A offering. Thank you for pointing this out to us and please accept our apologies. We hope to see you as an investor, The Quadrant Team

What valuation was given to the company in the latest funding round in Dec19?

Hello William, The valuation of the company following our last Regulation D common stock offering (December 2019) was approximately $222 Million. Please note that the shares purchased in the Regulation D offering in December are subject to 1 year holding period which is a significant liquidity restriction whereas the shares purchased through this Regulation A offering are freely transferable. We hope this explanation is helpful and that you choose to join us as an investor! Thanks, The Quadra...

What's the science behind testing for autism and other disease states that are primarily diagnosed through behavioral patterns?

Thank you for asking! This is game-changing technology which has been developed over the past 5 years by SUNY Upstate Medical University, the Penn State College of Medicine and Quadrant Biosciences. A quick video about our science is available here: https://vimeo.com/367101683 . Further, we’ve made a commitment to transparency in our work – our 7 peer-reviewed publications related to Autism Spectrum Disorder are available here: https://www.clarifiasd.com/our-science/ (but if you only have tim...

Hello ,is there any plan for future exit ( acquisition or going Public)?

This is a very savvy question – thank you. As you can likely intuit, this offering presages our intended public listing. As you may know, many of the requirements to offer securities in this Regulation A offering conform to the high standards of a public offering (i.e. financial statements audited by a PCAOB certified accounting firm); this offering will help us achieve other listing requirements as well (i.e. to list on NASDAQ, companies must also have at least 450 round lot shareholders or ...

Quadrant Biosciences Updates, Team, and Funding Progress | Wefunder, Home of the Community Round

Applied our expertise in RNA analysis to co-develop FDA authorized COVID-19 saliva test with SUNY.

Developed & commercialized world's first saliva based epigenetic test for autism spectrum disorder.

Sales from our new saliva COVID-19 tests have exceeded $6.5MM to date since September 2020.

We are working with NY State to test municipalities' wastewater for COVID-19.

Working with SUNY on pooled saliva surveillance of returning college students for COVID-19.

Development of Parkinson's disease, concussion, and Anorexia Nervosa, diagnostic tools in progress.

Our company is led by a former Chairman & CEO of Morgan Stanley Bank, Richard Uhlig.

Quadrant Biosciences

We develop novel, saliva based tests for Autism, COVID-19 and Parkinson's.

Never miss an update

What Investors Say

Quadrant Biosciences

Quick facts

Team profiles

Never miss an update

What Investors Say